title: Different modes of growth hormone (GH) administration do not change GH binding protein activity in man.
abstract: OBJECTIVE
  Studies in rodents have shown GH binding protein (GHBP) levels to be dependent on the mode of GH administration. The aim is to determine whether GHBP levels in man are also modulated by the pattern of GH administration.
  
  
  METHODS
  Six GH deficient subjects participated in a randomized study in which 2 IU GH were administered either as (i) a continuous 24-hour infusion, (ii) two intravenous boluses or (iii) eight intravenous boluses every 3 hours. In a second study, six normal men received a single subcutaneous injection of 0.2 U/kg GH and GHBP activity was measured over 24 hours. Control data were obtained from an untreated group of six age-matched normal men.
  
  
  METHODS
  GHBP activity was measured by immunoprecipitation using a monoclonal antibody that recognizes the human GHBP, and expressed as percentage specific binding of 125I-GH in 50 microliters of serum.
  
  
  RESULTS
  GHBP activity was not significantly different between the GH deficient and normal subjects. GHBP activity did not rise significantly during GH administration with each of the three intravenous patterns of delivery nor were there any significant differences between treatments. In the second study, GHBP activity did not change significantly following subcutaneous GH injection nor did results differ from untreated normal controls.
  
  
  CONCLUSIONS
  The level of GHBP in man is not dependent on GH secretory status or altered by short-term GH treatment or the mode of administration. These findings stand in contrast to GH treatment effects in rodents and suggest that GH regulation of GHBP may be different between species.
authors.affiliation: Garvan Institute of Medical Research, St Vincents Hospital, Sydney, NSW, Australia.
authors.forename: K K
authors.initials: KK
authors.lastname: Ho
authors.forename: J O
authors.initials: JO
authors.lastname: Jorgensen
authors.forename: E
authors.initials: E
authors.lastname: Valiontis
authors.forename: M J
authors.initials: MJ
authors.lastname: Waters
authors.forename: I A
authors.initials: IA
authors.lastname: Rajkovic
authors.forename: J S
authors.initials: JS
authors.lastname: Christiansen
mesh_terms: D000328:Adult; D002352:Carrier Proteins / Q000097:blood / Q000378:metabolism*; D004334:Drug Administration Schedule; D005260:Female; D006130:Growth Disorders / Q000097:blood / Q000378:metabolism; D013006:Growth Hormone / Q000008:administration & dosage* / Q000172:deficiency / Q000378:metabolism*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D011233:Precipitin Tests
chemical_list: D002352:Carrier Proteins; D013006:Growth Hormone; C051815:somatotropin-binding protein